- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Diffuse large B-cell lymphoma (DLBCL)
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Polatuzumab vedotin – November 2019
Polatuzumab vedotin: Powder for I.V. infusion 140 mg; Polivy®
Last updated
20 March 2020